Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.3% – Here’s Why

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price traded up 5.3% during trading on Wednesday . The company traded as high as $51.07 and last traded at $51.3950. 121,724 shares changed hands during trading, a decline of 66% from the average session volume of 362,152 shares. The stock had previously closed at $48.79.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PLSE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research report on Monday, August 10th. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Canaccord Genuity Group raised their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Stock Up 15.9%

The company has a 50 day moving average price of $38.88 and a 200-day moving average price of $28.41. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -47.83 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. On average, analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Liane Teplitsky purchased 1,001 shares of the stock in a transaction on Tuesday, September 1st. The stock was purchased at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 4,095 shares of company stock valued at $199,931 in the last quarter. Corporate insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its stake in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences during the 2nd quarter valued at $28,000. Tower Research Capital LLC TRC raised its holdings in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. boosted its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $158,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.